Dr. Gregory M. Gressel, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 55
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Tufts University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
MI license 4301503788 -
Gynecologic Oncology Physician
MI license 4301503788
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Spectrum Health Grand Rapids, MI
- Lakeland Hospital, St Joseph St Joseph, MI
- Spectrum Health United Hospital Greenville, MI
- Corewell Health Big Rapids Hospital Big Rapids, MI
- Corewell Health Zeeland Hospital Zeeland, MI
Medical groups
- Spectrum Health Primary Care PArtners (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 55
- Services billed
- 183
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Grand Rapids, MI | 45 |
| Ondansetron Hcl Other prescribers in Grand Rapids, MI | 40 |
| Megestrol Acetate Other prescribers in Grand Rapids, MI | 28 |
| Olanzapine Other prescribers in Grand Rapids, MI | 21 |
| Letrozole Other prescribers in Grand Rapids, MI | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 16 payments worth $19,843 in total to this clinician.
| Eisai Inc. | $7,937 |
|---|---|
| AbbVie Inc. | $5,041 |
| Pfizer Inc. | $3,500 |
| AstraZeneca Pharmaceuticals LP | $2,460 |
| GlaxoSmithKline, LLC. | $905 |
| Consulting Fee | $10,313 |
|---|---|
| Speaking at a medical education program | $4,978 |
| Compensation for services other than consulting (speaking, faculty) | $3,500 |
| Travel and Lodging | $696 |
| Food and Beverage | $357 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Oct 22, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $4,200 |
| Pfizer Inc. Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) TIVDAK · ONCOLOGY | $3,500 |
| Eisai Inc. Dec 9, 2025 | Speaking at a medical education program Lenvima · Oncology | $2,715 |
| AstraZeneca Pharmaceuticals LP Jun 26, 2025 | Consulting Fee | $2,460 |
| Eisai Inc. Feb 26, 2025 | Consulting Fee Lenvima · Oncology | $2,445 |
| Eisai Inc. Dec 9, 2025 | Speaking at a medical education program Lenvima · Oncology | $2,263 |
| GlaxoSmithKline, LLC. Jul 7, 2025 | Consulting Fee | $800 |
| AbbVie Inc. Aug 23, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to ROSEMONT, IL · in-kind | $492 |
| Eisai Inc. Sep 10, 2025 | Consulting Fee Lenvima · Oncology | $408 |
| AbbVie Inc. Aug 22, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to ROSEMONT, IL · in-kind | $204 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $18,822 in research payments for these studies, mostly to the institutions running them.
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.